BiomX Inc. (PHGE): Nasdaq/NYSE listing notice — BiomX wins NYSE American approval of compliance plan; has until Sep 2027

BiomX Inc.

NYSE American accepted BiomX's plan to regain compliance; plan period ends Sept 25, 2027.
Non-compliance stems from stockholders' deficit of $(1.302M) as of Dec 31, 2025.
Company continues trading on NYSE American with .BC indicator during plan period.
Plan submitted Apr 24, 2026; periodic NYSE Regulation reviews apply.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BiomX Inc. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

Exchange: nyse american
Notice: extension granted
Deficiency: stockholders equity
Rules: 1003(a)(i), 1003(a)(ii), 1003(a)(iii)

Exact text from the filing

iod through September 25, 2027 to regain compliance with the applicable continued listing standards. As previously disclosed, on March 25, 2026, the Company received written notice from NYSE Regulation that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the NYSE American LLC Company Guide (the “Company Guide”), which require a listed company to maintain specified levels of stockholders’ equity. The notice was based on the Company’s reported stockholders’ deficit of $(1,302,000) as of December 31, 2025 and

View on SEC.gov

95 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-068026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.